MariMed (MRMD) Expected to Post Earnings on Wednesday

MariMed (OTCMKTS:MRMD) is projected to post its Q3 2026 results after the market closes on Wednesday, November 11th. Analysts expect MariMed to announce earnings of ($0.01) per share and revenue of $41.20 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:00 AM ET.

MariMed (OTCMKTS:MRMD) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.01) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.01). MariMed had a negative return on equity of 10.71% and a negative net margin of 9.13%. The business had revenue of $41.92 million for the quarter, compared to the consensus estimate of $39.80 million.

MariMed Stock Down 2.0%

MRMD opened at $0.05 on Wednesday. The business has a 50 day moving average price of $0.07 and a 200 day moving average price of $0.07. MariMed has a twelve month low of $0.04 and a twelve month high of $0.16. The company has a debt-to-equity ratio of 1.78, a quick ratio of 0.34 and a current ratio of 0.92.

About MariMed

MariMed, Inc is a U.S.-based cannabis company that develops, operates and manages licensed cannabis cultivation, processing and dispensary facilities. The company serves both medical and adult-use markets, where permitted by state law, and focuses on producing and distributing cannabis flower, concentrates, edibles, tinctures and other cannabis-infused products.

MariMed markets products under brands that have included Betty’s Eddies, Nature’s Heritage, InHouse and Kalm Fusion. Its products are sold through the company’s retail operations and third-party dispensaries in its operating markets.